SCHEMBL2813768

SCHEMBL2813768

COc1ccc(C(=O)Nc2cccc(C(C)(C)CN)c2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.62
ALDH1A1 P00352 3/20 0.62
LMNA P02545 2/20 0.58
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
NQO2 P16083 1/20 0.55
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
TP53 P04637 3/20 0.54
PKM P14618 2/20 0.52
MAPT P10636 3/20 0.52
NR1H4 Q96RI1 1/20 0.50
PDE5A O76074 1/20 0.49
PDE1A P54750 1/20 0.49
PDE1B Q01064 1/20 0.49
PDE1C Q14123 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814428 0.87 KMT2A (0.60) POLBALDH1A1MEN1KMT2ANPC1
SCHEMBL2815254 0.86 POLB (0.65) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL2814215 0.85 POLB (0.65) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL27796788 0.84 ALDH1A1 (0.67) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL13561150 0.83 MAPT (0.68) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL2816049 0.81 POLB (0.62) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL2816881 0.81 RAB9A (0.54) POLBALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2816495 0.80 NPC1 (0.53) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL2816711 0.80 NPC1 (0.53) POLBALDH1A1MEN1KMT2ANPC1
SCHEMBL2819812 0.80 MAPT (0.56) POLBALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US claimed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP claimed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO claimed
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US disclosed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG POLB 3820/4885ALDH1A1 1769/4885LMNA 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.